Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026

1. Overview
The Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026 course provides a comprehensive exploration of the principles, clinical applications, and management of immuno-oncology therapies. The program covers checkpoint inhibitors, CAR T-cell therapy, and bispecific agents across various malignancies, while offering evidence-based strategies for recognizing and mitigating immune-related adverse events.
Course Date: Wednesday, January 28, 2026, 8:00 AM – 4:45 PM, Online
Immunotherapeutics have transformed the treatment landscape for patients with both solid tumors and hematologic malignancies. Since the landmark approval of ipilimumab, rapid and ongoing advancements in immunotherapy have continued to revolutionize clinical practice.
This one-day live virtual CME program will provide a comprehensive review of foundational concepts and emerging advances in cancer immunotherapy, tailored to the educational needs of physicians, advanced practice providers (APPs), and allied health professionals. Faculty experts will highlight clinical applications across solid and hematologic cancers, as well as strategies for recognizing and managing toxicity—including immune-related adverse events (irAEs) associated with immune checkpoint inhibition.
Presentations will cover the fundamentals of immune checkpoint blockade and CAR T-cell therapy, along with updates in TIL and BiTE therapies, novel combination approaches, and algorithmic management of irAEs. Toxicity management will be reinforced through case-based discussions illustrating common, rare, and severe presentations.
The goal of this program is to improve patient outcomes by advancing understanding of cancer immunology and enhancing the effective, evidence-based application of immunotherapeutic strategies in clinical practice.
Specialties
Specialties – Dermatology, Genitourinary Oncology, Hematology, Hepatology, Hospitalist, Immunotherapy, Leukemia, Lymphoma, Medical Oncology, Myeloma, Neuro-Oncology, Nurse Practitioner, Physician Assistant, Pulmonary Medicine, Solid Tumor Oncology
2. Learning Objectives

Identify and define foundational concepts of immunotherapy, including key immune system components, mechanisms of action, and types of immunotherapeutic agents.
Explain the biological rationale and mechanisms by which immunotherapy targets solid and hematologic malignancies, distinguishing between innate and adaptive immune responses.
Apply evidence-based immunotherapeutic approaches to the management of solid tumors and hematologic cancers, including appropriate patient selection, risk stratification, and development of individualized treatment plans.
Compare and contrast novel immunotherapy agents, including checkpoint inhibitors, bispecific antibodies, and immune agonists, in terms of efficacy, safety profiles, and mechanisms of action.
Evaluate the role of CAR T-cell therapy in current oncology practice, including patient eligibility, response rates, and long-term outcomes, and design a toxicity management plan for immune-related adverse events (irAEs) in immuno-oncology patients.

3. Target Audience

Best for oncologists and specialized nursing professionals who want foundational updates on immunotherapy protocols and adverse event management.

4. Topics

Advancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies

Advancing Leukemia Care Through Immuno-Oncology

Approaches to Immunotherapy-related Pneumonitis Management

Breast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes

Checkpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma

Clinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy

Discussion of Novel Checkpoint Inhibitors and Combination Therapy

Dostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights

Evolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer

IL-2-Stimulating Agents from Early Drug Development

Innovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab

Intrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video

Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4

Melanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-

Neurotoxicity in CAR T-Cell Therapy- Recognition and Management

Overview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias

Q&A and Discussion – 01

Q&A and Discussion – 02

Q&A and Discussion – 03

Q&A and Discussion – 04

Q&A and Discussion

Targeting Multiple Myeloma with Bispecific Immune-Modulating Agents

The Role of T-Cell Therapy in Standard Care for Synovial Sarcoma

Understanding Chimeric Antigen Receptor (CAR) T-Cell Therapy